Clinical Trials Logo

SARS-CoV2 Infection clinical trials

View clinical trials related to SARS-CoV2 Infection.

Filter by:

NCT ID: NCT06247059 Not yet recruiting - SARS-CoV2 Infection Clinical Trials

Reducing Respiratory Virus Transmission in Bangladeshi Classrooms

Start date: December 2024
Phase: N/A
Study type: Interventional

This study will test if affordable air cleaning devices (box fans with a filter attached and/or ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience.

NCT ID: NCT06181292 Active, not recruiting - SARS-CoV2 Infection Clinical Trials

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

Start date: November 13, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

NCT ID: NCT06175611 Recruiting - SARS-CoV2 Infection Clinical Trials

Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection

Start date: December 10, 2023
Phase:
Study type: Observational [Patient Registry]

The primary objective of this clinical performance study is to evaluate and further validate the clinical performance of: 1. ClariLight Influenza A/B & SARS-CoV-2 test kits and 2. ClariLight Influenza A/B & RSV test kits, for the qualitative detection and differential diagnosis of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) present in anterior nasal and oropharyngeal swab, in combination with an automated molecular diagnostic analyzer and sample collection tube by comparing them against a CE marked, in-vitro diagnostic device, used in the standard of care.

NCT ID: NCT06085547 Recruiting - SARS-CoV2 Infection Clinical Trials

Rural Tailored Communication to Promote SARS-CoV-2 Antibody Testing in Saliva

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This study seeks to evaluate communication strategies for better encouraging understanding and uptake of salivary SARS-CoV-2 antibody testing among individuals residing in rural Northern Michigan. This iteration will consider individuals recruited from rural Northern Michigan and assess their willingness to participate in home-based saliva sample collections.

NCT ID: NCT05852873 Recruiting - COVID-19 Clinical Trials

PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway

PanoramicNOR
Start date: May 12, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo. Participants with acute COVID-19, documented with positive lateral flow test or PCR, within the last 5 days will be randomised to take either Paxlovid or placebo. All participants will receive standard of care in addition. Participants will respond to electronic questionnaires at 14 time points during follow-up. The primary outcome is presence of long-COVID symptoms at 3 months follow-up. Researchers will compare participants who received Paxlovid and placebo to see if Paxlovid treatment can prevent the occurrence of long-COVID.

NCT ID: NCT05729204 Completed - SARS-CoV2 Infection Clinical Trials

Washing COVID-19 Away With a Hypertonic Seawater Nasal Irrigation Solution

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Nasal irrigations are thought to reduce the amount of virus from the nasal cavity. The aim of the present study is to evaluate the effect of a hypertonic seawater solution containing algal and herbal natural ingredients (Sinomarin®) on the nasopharyngeal viral load in hospitalized patients with severe COVID-19 pneumonia. The investigators will conducted a prospective, randomized, controlled trial. Patients will be allocated in two groups, the hypertonic seawater group receiving nasal irrigations with a hypertonic seawater solution (Sinomarin®) every 4 hours during a 16-hour interval per day, for two consecutive days, and the control group (no nasal irrigations). Forty-eight hours after the baseline nasopharyngeal swab (and 8 hours after the last wash in the hypertonic seawater group), a second nasopharyngeal swab will be collected for the semiquantitative estimation of the SARS-CoV-2 viral load as determined by cycle threshold (Ct) values.

NCT ID: NCT05638620 Active, not recruiting - Long COVID Clinical Trials

Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID

DSBLongCOVID
Start date: January 3, 2023
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

NCT ID: NCT05607147 Completed - SARS-CoV2 Infection Clinical Trials

Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing

PREDICT-DHCW
Start date: January 26, 2021
Phase: N/A
Study type: Interventional

10 asymptomatic DHCWs in the Oral Medicine clinic, Rutgers School of Dental Medicine, with no history of documented COVID-19 infection or viral exposure, were enrolled in a study that interrogated DHCWs' perceptions of safety and adoption of risk mitigation behavior. Following a baseline survey, finger-prick blood samples were collected twice two weeks apart using an innovative microsampling technique that replaces the need for venipuncture. Samples were processed using an in-house ELISA assay to detect IgM and IgG directed against the Receptor Binding Domain (RBD) of the Spike protein. Weekly Rapid Antigen testing of nasal swab specimens was used to document Antigen negativity during the study.

NCT ID: NCT05607043 Completed - SARS-CoV2 Infection Clinical Trials

Rutgers Pilot for PREDICT- Patient LAB Test

Start date: January 31, 2021
Phase: N/A
Study type: Interventional

A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral RNA using an FDA approved RT-PCR test for SARS-CoV2- an RNA RT-PCR assay (Accurate Diagnostics)

NCT ID: NCT05593770 Active, not recruiting - COVID-19 Clinical Trials

International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

NECTAR
Start date: October 27, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.